Regenosine
Founded 2018 · 2 employees on LinkedIn · 3 known investors
Regenosine develops regenerative medicine therapies for musculoskeletal and orthopedic conditions. The company leverages adenosine-based science to address inflammatory diseases and tissue healing.
Founders & leadership
Regenosine was founded in 2018 by Dr. Siddhesh Angle and Dr. Bruce Cronstein.
Investors · 3
Company profile
researched Aug 2026Regenosine is a musculoskeletal regenerative medicine company developing first-in-class therapies for osteoarthritis (OA) and other indications with unmet clinical need. Its platform is built on the purinergic system, specifically adenosine signaling and the adenosine A2A receptor, which the company describes as critical to maintaining cartilage and musculoskeletal tissue homeostasis. The lead asset is a proprietary, patented liposomal adenosine formulation delivered by intra-articular injection, designed to release adenosine slowly over a period of up to 15 days within the joint.
The company positions the product as disease-modifying rather than symptomatic, with stated aims of reducing joint pain, halting radiological and histological progression of OA, and regenerating cartilage in joints with established disease. It targets the joint preservation market and frames its value proposition around improved clinical outcomes, patient quality of life, and lower total healthcare delivery costs associated with osteoarthritis. Regenosine is listed in the startup portfolio of NYU and NYU Langone Health's Technology Opportunities & Ventures office, with Bruce N. Cronstein, MD as principal investigator.
Founding story
Regenosine was co-founded by Bruce Cronstein, MD, who is credited with first discovering the anti-inflammatory effects of adenosine and its role in wound healing, cartilage homeostasis and OA treatment, and who serves as Chair of the company's Scientific Advisory Board. Siddhesh Angle, PhD, is founder, President and Chief Executive Officer; his background spans roughly 15 years in musculoskeletal research and development, including a role in the acquisition of a synthetic biomaterials start-up by Zimmer Biomet and subsequent work as R&D Manager for Zimmer Biomet's Global Biologics business, where he commercialized orthopedic medical devices and combination therapies. The company appears in the NYU/NYU Langone Health startup portfolio with a listed year of 2019.
Traction
Development is at the preclinical/translational stage, supported by animal efficacy studies in rat post-ACL-rupture and diet-induced obesity mouse OA models, a set of peer-reviewed publications, an independent third-party efficacy evaluation, and issued/pending patents on the slow-release adenosine formulations. The company is listed as an active startup in the NYU and NYU Langone Health venture portfolio.
▸Full profile — market position, technology, go-to-market, geography, risks & controversies
Market position
Regenosine describes its candidate as the only disease-modifying osteoarthritis therapy currently in development and as first-in-class, contrasting it with existing technologies that address symptoms rather than the underlying disease. It targets what it characterizes as a rapidly growing joint preservation market.
Technology
The technology is based on the purinergic system's role in cartilage homeostasis. Company materials state that absence of the adenosine A2A receptor can cause spontaneous osteoarthritis in mice and that chondrocytes from OA patients generate substantially less adenosine than normal chondrocytes. Because free adenosine has a half-life of only 1-2 seconds in biological fluids, the core intellectual property lies in formulations that prolong adenosine activity; the lead formulation encapsulates adenosine in liposomes for slow release of up to 15 days after intra-articular injection. Two assets are described in the development pipeline. Preclinical testing used a rat model of established OA following ACL rupture and a mouse model of obesity-induced OA; in both, restoring joint adenosine levels was reported to prevent OA progression, reverse cartilage degradation and restore cartilage thickness, while reducing joint pain and inflammation, activating TGF-beta signaling associated with chondrocyte proliferation and maturation, and downregulating cell-death factors. The company also cites an independent third-party evaluation reporting long-term pain relief, functional recovery, improved range of motion and reduced radiological and histological signs of OA progression in clinically relevant models. Supporting peer-reviewed publications include papers in Nature Communications (2017), Scientific Reports (2019 and 2020), FASEB J (2020), Biochemical Pharmacology (2018), Inflammation (2018) and Purinergic Signalling (2016).
Go-to-market
Patients with established osteoarthritis treated via intra-articular injection, with additional indications of unmet clinical need cited as future targets.
Geography
Associated with NYU and NYU Langone Health in the United States through its technology transfer and startup portfolio relationship.
Risks & controversies
Reported efficacy results derive from animal models rather than human clinical trials, and the company publishes a financial conflict-of-interest policy for NIH-supported research.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
In the news
▸Research sources · 8
primary sources listed
- Regenosineregenosine.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Regenosine do?
- Preclinical biotech developing a slow-release liposomal adenosine intra-articular injection as a disease-modifying osteoarthritis therapy.
- Who founded Regenosine?
- Regenosine was founded by Dr. Siddhesh Angle, Dr. Bruce Cronstein in 2018.
- Who are Regenosine's investors?
- Regenosine's investors include Beresford Ventures, NYU Innovation Venture Fund, Tech Council Ventures.